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Laurence J. M. Cross1,2, Cecilia M. O’Kane1, Cliona McDowell3, Jospeh J. Elborn1, Michael A. Matthay4,5
and Daniel F. McAuley1,2*Erratum
In the original publication [1] the last sentence under
the paragraph “Adverse event management” not correct.
The correct version can be found here:
“SAEs that occur between trial entry and up to 28 days
after completion of the study drug will be reported”.
Author details
1Centre for Infection and Immunity, The Queen’s University of Belfast, Health
Sciences, Building, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland.
2Regional Intensive Care Unit, Royal Victoria Hospital, Belfast Health and
Social Care Trust, Grosvenor Road, Belfast BT12 6BA, Northern Ireland.
3Clinical Research Support Centre, Royal Victoria Hospital, Belfast Health and
Social Care Trust, Grosvenor Road, Belfast BT12 6BA, Northern Ireland.
4Cardiovascular Research Institute, University of California, San Francisco, 505
Parnassus Avenue, M-917, San Francisco, CA 94143-0624, USA. 5Departments
of Medicine and Anesthesia, University of California, San Francisco, 505
Parnassus Avenue, San Francisco, CA 94143, USA.
Received: 6 April 2017 Accepted: 6 April 2017
Reference
1. McAuley DF. Keratinocyte growth factor in acute lung injury to reduce
pulmonary dysfunction – a randomised placebo-controlled trial (KARE):
study protocol. Trials. 2013;14:10.1186/1745-6215-14-51.* Correspondence: d.f.mcauley@qub.ac.uk
1Centre for Infection and Immunity, The Queen’s University of Belfast, Health
Sciences, Building, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland
2Regional Intensive Care Unit, Royal Victoria Hospital, Belfast Health and
Social Care Trust, Grosvenor Road, Belfast BT12 6BA, Northern Ireland
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
